Wall, Street

Wall Street Analysts Temper Outlook for Procter & Gamble Ahead of Earnings

09.01.2026 - 10:46:04

Procter & Gamble US7427181091

A wave of caution is sweeping through Wall Street regarding Procter & Gamble. As the consumer goods behemoth approaches its quarterly earnings release, several prominent analyst firms have trimmed their price targets for the company's shares, citing concerns over near-term growth prospects for fiscal 2026.

The most significant adjustment came from investment bank TD Cowen on January 8. The firm's strategists slashed their target price for P&G shares to $150, down sharply from a previous target of $168—a reduction exceeding 10%. While they maintained a "buy" rating, the substantial cut signals diminished confidence in the stock's immediate trajectory.

This move followed a similar action by Wells Fargo just days earlier. Analysts there lowered their price objective from $170 to $158 per share. They attributed the revision to updated financial models for the beverage, food, household, and personal care segments, which point to a more challenging operating environment in 2026.

Upcoming Quarterly Report in Focus

Market participants are now looking ahead to January 22, 2026, when Procter & Gamble is scheduled to disclose its results for the second fiscal quarter. Consensus estimates currently project revenue of approximately $22.36 billion and earnings per share (EPS) of $1.87.

Should investors sell immediately? Or is it worth buying Procter & Gamble?

In the prior quarter, the company managed to post a 3% revenue increase. However, management's relatively subdued full-year guidance, forecasting growth only in the low-to-mid single digits, has tempered market enthusiasm.

Regulatory Settlement Reached

Separate from its financial performance, P&G has resolved a regulatory matter. The company reached a settlement with the Texas Attorney General concerning the packaging design of its "Crest" children's toothpaste. As part of the agreement, P&G will introduce new packaging starting in January that more clearly illustrates appropriate dosing for children. This action follows a comparable settlement reached by a competitor in September of last year.

Valuation and Investor Perspective

Despite the recent cautious analyst commentary, P&G shares are currently trading at $141.53. With a price-to-earnings (P/E) ratio hovering around 20.4 and a dividend yield near 3%, the so-called "dividend king" remains a core holding for many portfolios. Nevertheless, the recent series of target price reductions suggests the equity's near-term upside may be constrained. The upcoming earnings release on January 22 is widely seen as a pivotal event for the company to restore Wall Street's confidence.

Ad

Procter & Gamble Stock: Buy or Sell?! New Procter & Gamble Analysis from January 9 delivers the answer:

The latest Procter & Gamble figures speak for themselves: Urgent action needed for Procter & Gamble investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from January 9.

Procter & Gamble: Buy or sell? Read more here...

@ boerse-global.de